Sana Biotechnology annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Sana Biotechnology Stock-Based Compensation Growth & History (SANA)
Sana Biotechnology's stock-based compensation was $25.5M for fiscal 2025.
View full Sana Biotechnology company overviewSana Biotechnology annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.5M | −$12.2M | −32.42% |
| 2024 | 2024-12-31 | $37.7M | $2.1M | +6.04% |
| 2023 | 2023-12-31 | $35.5M | −$2.8M | −7.31% |
| 2022 | 2022-12-31 | $38.3M | $16.0M | +71.44% |
| 2021 | 2021-12-31 | $22.4M | $16.5M | +283.70% |
| 2020 | 2020-12-31 | $5.8M | $4.3M | +289.31% |
| 2019 | 2019-12-31 | $1.5M | — | — |
Sana Biotechnology quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.3M | −$1.3M | −19.41% |
| Q1 2026 | 2026-03-31 | $5.7M | −$1.4M | −19.37% |
| Q4 2025 | 2025-12-31 | $6.3M | −$99,000 | −1.54% |
| Q3 2025 | 2025-09-30 | $5.5M | −$5.3M | −49.16% |
| Q2 2025 | 2025-06-30 | $6.6M | −$4.8M | −41.75% |
| Q1 2025 | 2025-03-31 | $7.0M | −$2.1M | −22.77% |
| Q4 2024 | 2024-12-31 | $6.4M | −$1.5M | −18.85% |
| Q3 2024 | 2024-09-30 | $10.8M | $1.8M | +19.63% |
| Q2 2024 | 2024-06-30 | $11.4M | $1.5M | +15.56% |
| Q1 2024 | 2024-03-31 | $9.1M | $341,000 | +3.90% |
| Q4 2023 | 2023-12-31 | $7.9M | −$2.7M | −25.12% |
| Q3 2023 | 2023-09-30 | $9.0M | −$1.1M | −10.68% |
| Q2 2023 | 2023-06-30 | $9.8M | −$63,000 | −0.64% |
| Q1 2023 | 2023-03-31 | $8.8M | $996,000 | +12.84% |
| Q4 2022 | 2022-12-31 | $10.6M | $3.3M | +44.82% |
| Q3 2022 | 2022-09-30 | $10.1M | $4.1M | +69.41% |
| Q2 2022 | 2022-06-30 | $9.9M | $5.0M | +100.59% |
| Q1 2022 | 2022-03-31 | $7.8M | $3.6M | +86.51% |
| Q4 2021 | 2021-12-31 | $7.3M | $4.5M | +162.02% |
| Q3 2021 | 2021-09-30 | $6.0M | $4.8M | +410.29% |
| Q2 2021 | 2021-06-30 | $4.9M | $3.8M | +342.74% |
| Q1 2021 | 2021-03-31 | $4.2M | $3.4M | +450.73% |
| Q4 2020 | 2020-12-31 | $2.8M | — | — |
| Q3 2020 | 2020-09-30 | $1.2M | — | — |
| Q2 2020 | 2020-06-30 | $1.1M | — | — |
| Q1 2020 | 2020-03-31 | $755,000 | — | — |
Sana Biotechnology stock-based compensation trends
Over the last five fiscal years, Sana Biotechnology's stock-based compensation increased from $5.8M to $25.5M, a change of $19.6M. The latest reported quarter, Q2 2026, shows $5.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sana Biotechnology source filings ↗